Aoife Brennan
Chief Medical Officer, SYNLOGIC, INC.
Companies
- Climb Bio, Inc.Board member Jun 27, 2024 to now1
- Climb Bio, Inc.Chief executive officer Jun 27, 2024 to now1
- Climb Bio, Inc.President Jun 27, 2024 to now1
- Xilio Therapeutics, Inc.Board member Jun 17, 2024 to now2
- KYNTRA BIO, INC.Board member Aug 7, 2020 to Jun 6, 20243
- SYNLOGIC, INC.Board member Nov 1, 2018 to Nov 14, 20234
- SYNLOGIC, INC.Chief executive officer Jun 6, 2018 to Nov 14, 20235
- SYNLOGIC, INC.President Jun 6, 2018 to Nov 14, 20235
- SYNLOGIC, INC.Chief Medical Officer Aug 30, 2017 to Apr 5, 20236
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- Climb Bio, Inc. CLYM87,731 shares7$861.5K at $9.82Jun 29, 2026
- SYNLOGIC, INC. SYBX256,301 shares8$276.8K at $1.08Apr 3, 2023
- KYNTRA BIO, INC. KYNB27,947 shares9$145.9K at $5.22Jun 9, 2023
As of each latest filing. The line shows shares held over time.
Recent filings
- Jun 29, 2026Sold 30,902 shares at $13.17 of Climb Bio, Inc.7
- Jun 27, 2026Exercised options 68,750 shares of Climb Bio, Inc.7
- Jun 30, 2025Sold 20,618 shares at $1.22 of Climb Bio, Inc.10
- Jun 27, 2025Exercised options 68,750 shares of Climb Bio, Inc.10
- Jun 9, 2023Sold 2,739 shares at $17.52 of KYNTRA BIO, INC.9
- Jun 9, 2023Sold 1,994 shares at $16.74 of KYNTRA BIO, INC.9
- Jun 7, 2023Granted 8,289 shares of KYNTRA BIO, INC.9
- Apr 3, 2023Sold 19,042 shares at $0.58 of SYNLOGIC, INC.8
- Jun 16, 2022Granted 15,777 shares of KYNTRA BIO, INC.11
- Apr 4, 2022Sold 8,894 shares at $2.45 of SYNLOGIC, INC.12
- Feb 4, 2022Granted 106,920 shares of SYNLOGIC, INC.13
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARClimb Bio, Inc., Board member
- 2
- 3SEC EDGARKYNTRA BIO, INC., Board member
- 4SEC EDGARSYNLOGIC, INC., Board member
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARForm 4 filed Jul 1, 2025
- 11SEC EDGARForm 4 filed Jun 21, 2022
- 12SEC EDGARForm 4 filed Apr 6, 2022
- 13SEC EDGARForm 4 filed Feb 8, 2022